

Liver Failure

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT02621047 2015-002976-25
NP29783

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter, non-randomized, single-dose, open-label study conducted in male and surgically sterile or post-menopausal female participants with stable chronic hepatic impairment and in healthy participants matched by age, gender, and body weight to assess the effect of hepatic impairment on the pharmacokinetics of alectinib.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02621047 2015-002976-25 NP29783
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 18 Years & <= 70 Years

Healthy Volunteers
Accepts Healthy Volunteers
